China grants conditional approval for Merck’s COVID treatment, Health News, ET HealthWorld


Molnupiravir, developed by Merck which is also known as MSD outside the United States and Canada, is approved to be used in adult patients who have mild to medium COVID infection and a high risk of progressing to severe cases.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *